B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Obinutuzumab is a novel glycoengineered, type-II anti-CD20 monoclonal antibody that was recently developed to treat follicular lymphoma (FL), the most prevalent subtype of indolent B-cell lymphoma.
|
31848991 |
2020 |
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD52 and CD20 are co-expressed on the cell surface of malignant B cells in B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL) and increased expression of both antigens is detected on dividing or recently divided cells ("proliferative fraction") in CLL.
|
30145356 |
2019 |
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Monoclonal antibodies targeting CD20 are central in the treatment of B-cell lymphomas.
|
31669559 |
2019 |
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Soon after the anti-CD20 monoclonal antibody rituximab began to change the management of indolent and aggressive B cell lymphomas, development of alternative antibodies - including chemoimmunoconjugates - was undertaken.
|
30668192 |
2019 |
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings indicate that the number of NK cells in peripheral blood may affect the outcome of patients with B-cell non-Hodgkin lymphoma receiving anti-CD20-based immunochemotherapy.
|
31053601 |
2019 |
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD20 expression by malignant lymphocyte-predominant cells, a tendency for late relapses, and the risk of transformation to aggressive large B-cell lymphoma are characteristic features with important implications for treatment and follow-up.
|
30485408 |
2019 |
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The majority of B cell lymphomas express CD20, making it a valuable target both for antibody-based therapy and imaging.
|
30456475 |
2019 |
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Specificity of binding was confirmed using CD20 antibody mutants to human B-cell lymphoma cells.
|
31548565 |
2019 |
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
The CD-20 antibody rituximab is a standard component of treatment of non-Hodgkin B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL).
|
31418878 |
2019 |
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
We suggest that clinicians should consider that patients with long-standing pemphigus, both vulgaris and foliaceus, may develop primary cutaneous B-cell lymphomas, as shown in our report, and in these cases the treatment with rituximab is elective, providing a therapeutic option for both low-grade or follicular, CD20-positive, B-cell non-Hodgkin lymphomas and pemphigus.
|
31025498 |
2019 |
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
CD20 is the first-line diagnostic marker of B-cells, which serves as the target of the therapeutic monoclonal antibodies in B-cell lymphomas and leukemias.
|
29079175 |
2018 |
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This discussion focuses on diagnostic pitfalls related to the use of immunohistochemistry for CD20 and CD3 in hematopathology, and specifically on diagnostic challenges that arise when (1) CD20 is not expressed in B-cell lymphomas, when (2) CD20 is expressed in plasma cell neoplasms and T-cell lymphomas, and when (3) CD3 is expressed in B-cell lymphomas and Hodgkin lymphoma.
|
28914619 |
2018 |
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Human Serum Albumin-Based Drug-Free Macromolecular Therapeutics: Apoptosis Induction by Coiled-Coil-Mediated Cross-Linking of CD20 Antigens on Lymphoma B Cell Surface.
|
30259654 |
2018 |
B-Cell Lymphomas
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base.
|
29019447 |
2018 |
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
These tumor cells were immunohistologically positive for CD10 and CD20 and negative for B-cell lymphoma (BCL) 2 and BCL6.
|
29678710 |
2018 |
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
We produced an anti-CD20-IFN fusion protein containing the potent type 1 IFN isoform alpha14 (α14), and demonstrated its ability to suppress proliferation and induce apoptosis of human B cell lymphomas.
|
29920129 |
2018 |
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ENKTCL with both CD20-positive expression and the monoclonal rearrangement of IgH gene may be mistaken for B-cell lymphoma; thus, the comprehensive evaluation of histomorphology, more extensive immunoprofiles and molecular studies is essential to reach the correct diagnosis.
|
29063643 |
2018 |
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
CD20 antibody-loaded CD20<sup>+</sup> B-cell lymphoma cell lines were cultured with NK cells and ADCC activity was determined by lactate dehydrogenase release assays.
|
30132083 |
2018 |
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
The cytotoxic activity of the ADC was evaluated against Raji (human B-cell lymphoma; CD20-positive) and MOLT-4 (T lymphoblast; acute lymphoblastic leukemia; CD20-negative) cell lines.
|
29523024 |
2018 |
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
This phase II study recruited Japanese patients with previously untreated CD20+ B-cell non-Hodgkin lymphoma.
|
30060000 |
2018 |
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
slan<sup>+</sup> Monocytes and Macrophages Mediate CD20-Dependent B-cell Lymphoma Elimination via ADCC and ADCP.
|
29748373 |
2018 |
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
For the last 2 decades, anti-CD20 monoclonal antibodies have revolutionized the treatment of patients with B-cell lymphomas.
|
30190022 |
2018 |
B-Cell Lymphomas
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Radioimmunotherapies with monoclonal antibodies to the B-lymphocyte antigen 20 (CD20) are effective treatments for B-cell lymphomas, but U.S. Food and Drug Administration-approved radioimmunotherapies exclusively use radiolabeled murine antibodies, potentially limiting redosing.
|
29348316 |
2018 |
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Ofatumumab is a CD20 monoclonal antibody with activity against human B-cell lymphomas.
|
29517616 |
2018 |
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In light of their lymphoplasmacytoid features and CD20 expression, we speculated that they may share laboratory features with B-cell lymphomas with plasmacytic differentiation (BCL-PCDs).
|
29214874 |
2018 |